Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $24.50.

A number of brokerages have recently commented on KURA. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a report on Monday, April 28th. Mizuho lowered their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Wall Street Zen lowered Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, JMP Securities restated a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a report on Tuesday, April 29th.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of the company. State of Wyoming purchased a new stake in Kura Oncology during the first quarter worth approximately $48,000. Virtus ETF Advisers LLC lifted its holdings in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC purchased a new stake in Kura Oncology during the 1st quarter worth $66,000. Flower City Capital acquired a new stake in Kura Oncology in the 1st quarter valued at $79,000. Finally, Magnetar Financial LLC acquired a new stake in Kura Oncology in the 1st quarter valued at $79,000.

Kura Oncology Price Performance

NASDAQ KURA traded down $0.14 during trading hours on Thursday, reaching $5.68. The company's stock had a trading volume of 880,510 shares, compared to its average volume of 1,201,478. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company's 50-day moving average is $6.11 and its two-hundred day moving average is $8.03. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The stock has a market cap of $491.75 million, a PE ratio of -2.41 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. Analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.